Yettaw surmises apartments near university of minnesota twin cities and what twin babies clothes informs motive he had," Nyan Win told reporters.(Writing by Martin Petty; Editing by David Fox) World. OKLAHOMA CITY, OKLAHOMA, Jun 25 (MARKET WIRE) -- PRECISION PETROLEUM CORPORATION (OTCBB: PPTO) - Precision PetroleumCorporation (Nevada Company) (the "Company") has recently completed thepurchase of a working interest in an oil and gas lease in Garvin County,Oklahoma.Ward/McNeil #1 represents the 13th working interest purchased by theCompany over the past 2 months.This well was initially completed in the Basal PennsylvanianSandstone/Viola Limestone reservoirs after a minor frac entry into theseformations.The well was producing approximately 12 barrels of oil and 100 MCF ofnatural gas per day after the initial treatment. The Company intends tore-enter these formations with a major frac which should substantiallyincrease the production capacity of the reservoirs.Richard Porterfield, Petroleum Geologist and President, is pleased withthis acquisition. Although the well is presently considered a minorproducer, we anticipate that we will be able to quickly recover ourinvestment and extended profits after the re-completion is finalized.Mr.
Porterfield also stated that he and other oil and gas consultants arepresently assessing the acquisition of a 6 well producing package baseball managers . Thisoperation also has an abundance of spacing for a further 6 well expansiondevelopment, with multiple reservoirs twin babies clothing . In view of current commodityprices, this addition would be a major boost to the Company's cash flowand bottom line profits twin babies gifts . Negotiations have commenced during which varioustechnical analysis examinations and reservoir evaluation programs by theCompany are underway.Precision Petroleum Corporation is an independent energy company engagedin the acquisition, exploration and development of oil and natural gasproperties in North America twin babies products . Precision's objective is to seek out anddevelop opportunities in the oil and natural gas sectors that represent alow risk opportunity.
As well, Precision aims to define larger projectsthat can be developed with Joint Venture partners baseball tickets . More information aboutthe company is available at statements in this news release may contain forward-lookinginformation within the meaning of Rule 175 under the Securities Act of1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and aresubject to the safe harbor created by those rules twin baby apparel . All statements, otherthan statements of fact, included in this release, including, withoutlimitation, statements regarding potential future plans and objectives ofthe company, are forward-looking statements that involve risks anduncertainties twin baby clothes . There can be no assurance that such statements will proveto be accurate and actual results and future events could differmaterially from those anticipated in such statements twin baby clothing . The Company doesnot intend to, and undertakes no duty to, update any such forward lookingstatements to reflect the impact of circumstances or events that ariseafter the date such forward looking statements were made.Contacts:Precision Petroleum 2009, Market Wire, All rights reserved.-0-.
Transave Receives $2.2 Million Cystic Fibrosis Foundation Award forDevelopment of ARIKACE(TM)Company Also Receives Patent Covering ARIKACE for Once-Daily Treatment ofPseudomonas Lung InfectionsMONMOUTH JUNCTION, N.J., June 25 /PRNewswire/ -- Cystic Fibrosis FoundationTherapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation,has provided a $2.2 million award to Transave Inc., for the continueddevelopment of ARIKACE(TM) (liposomal amikacin for inhalation), an antibioticthat aims to treat Pseudomonas lung infections in cystic fibrosis (CF) andnon-CF bronchiectasis patients.Transave announced today that the award willbe used to support an ongoing Phase II clinical trial in U.S joe mauer . CF patients withPseudomonas lung infections and a preclinical study.The company alsoreported today completion of enrollment for its second CF Phase II clinicaltrial; results are expected to be available in July twin baby gift . The first CF Phase IItrial, completed in June 2008, achieved positive results.In other developments, the company announced that it was granted a patent forARIKACE by the U.S Patent and Trademark Office.U.S Patent No twin babies clothes . 7,544,369entitled "Sustained Release of Antiinfectives" covers ARIKACE for theonce-daily treatment of Pseudomonas lung infections."We have followed and supported Transave's work in this area from thebeginning, and we are excited to play a role in potentially bringing anothernew treatment option to CF patients," said Robert J twin babies clothing . Eighteen clinical sites throughout the United States are participating in thestudy.About ARIKACE(TM)ARIKACE is a sustained-release formulation of the antibiotic amikacin, whichencloses the drug in nanocapsules of lipid called liposomes. This advancedpulmonary liposome technology prolongs the release of amikacin in the lungswhile minimizing systemic exposure. The treatment uses biocompatible lipidsendogenous to the lung that are formulated into small (0.3 micron), neutralliposomes that enable penetration of the biofilm and are highly efficient,with a very low lipid-to-drug ratio (0.65).
ARIKACE can be delivered throughnebulization, which enables the small aerosol droplet size (1 to 5 microns) tofacilitate more effective distribution in the lungs.Positive Phase II results were announced in June 2008 from a clinical trial inEuropean CF patients with Pseudomonas lung infections.The company alsopreviously announced completion of enrollment in another Phase II trial inwhich ARIKACE is being evaluated in the treatment of non-CF patients who havebronchiectasis with Pseudomonas lung infections joe mauer jerseys . In the bronchiectasis trial,64 adult patients were randomized 2:1 to two doses -- either 280 mg or 560 mgof ARIKACE or placebo for 28 days followed by a 28-day off-treatmentobservation period.Sixteen clinical sites throughout Europe and India areparticipating in the bronchiectasis study twin babies gifts . ARIKACE has been granted orphan drug status in the United States by the FDA,and has received an orphan drug designation in Europe by the EuropeanMedicines Agency for the treatment of Pseudomonas infections in patients withCF.About The Cystic Fibrosis FoundationThe Cystic Fibrosis Foundation, the leading organization in the United Statesdevoted to curing and controlling cystic fibrosis, has invested more than $320million in drug research with biotech companies since 1998 to developtherapies to fight CF twin babies products . As a result, the Foundation has built a drug pipelinewith more than 30 promising therapies in development . Virtually every approvedCF therapy available today was made possible because of the support of theFoundation.
Comments are closed.